Table 1 Clinicopathological characteristics for patients 1-10 (PT1-PT10) and final RNA-seq samples
Patient | Sample | PT1 | PT2 | PT3 | PT4 | PT5 | PT6 | PT7 | PT8 | PT9 | PT10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
DAN | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 2 | |
PAN | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 4 | |
CAN | 2 | 1 | 2 | 1 | 3 | 1 | 3 | 2 | 4 | 4 | |
MET | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 0 | 0 | 0 | |
LYMPH | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
Age at RP, years | 61 | 51 | 67 | 49 | 63 | 64 | 69 | 65 | 52 | 68 | |
Pre-operative PSA, ng/mL | 21.0 | 28.9 | 18.1 | 47.1 | 5.6 | 22.6 | 155 | 7.0 | 20.6 | 7.2 | |
Pathological Gleason Score | 7 | 6 | 7 | 8 | 7 | 7 | 7 | 7 | 7 | 7 | |
CAN 1 | 4 + 3, | 3 + 3 | 4 + 4, | 4 + 3 | 3 + 3, | 3 + 4 | 4 + 4, | 3 + 4 | 3 + 4 + 5, | 3 + 3, | |
CAN 2 | 4 + 5 | 4 + 3 | 4 + 4, | 3 + 3, | 4 + 4 | 3 + 3, | 3 + 3, | ||||
CAN 3 | 4 + 5 | 4 + 4 | 3 + 4 + 5, | 3 + 4, | |||||||
Gleason gradesa | 3 + 4 | 4 + 4 | |||||||||
MET 1 | 4 + 3 | 4 + 3 | 4 + 5 | 4 + 5 | 4 + 4 | 4 + 4 | |||||
MET 2 | 4 + 5 | ||||||||||
MET 3 | — | ||||||||||
pT | pT3 | pT3 | pT3 | pT3 | pT3 | pT3 | pT3 | pT3 | pT3 | pT3 | |
pN | pN1 | pN1 | pN1 | pN1 | pN1 | pN1 | pN1 | pN1 | pN1 | pN1 |
